.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
Accenture
Harvard Business School
Julphar
Federal Trade Commission
Queensland Health
Novartis
Express Scripts
US Army
Colorcon

Generated: November 25, 2017

DrugPatentWatch Database Preview

Claims for Patent: 5,601,839

« Back to Dashboard

Claims for Patent: 5,601,839

Title: Triacetin as a penetration enhancer for transdermal delivery of a basic drug
Abstract:A composition and method for enhancing transdermal penetration of a basic drug are described. The composition comprises a matrix patch comprising an effective amount of a basic drug, preferably having a pK.sub.a of about 8.0 or greater, an effective amount of penetration enhancer consisting essentially of triacetin, and a polymer later preferably comprising a pressure-sensitive adhesive. A preferred basic drug is oxybutynin and acid addition salts thereof. The method for enhancing transdermal penetration comprises applying the matrix patch to a selected area of skin.
Inventor(s): Quan; Danyi (Salt Lake City, UT), Deshpanday; Ninad A. (Salt Lake City, UT), Venkateshwaran; Srinivasan (Salt Lake City, UT), Ebert; Charles D. (Salt Lake City, UT)
Assignee: TheraTech, Inc. (Salt Lake City, UT)
Application Number:08/429,757
Patent Claims: 1. A method of enhancing the rate of transdermal penetration of a basic drug having a pK.sub.a of about 8.0 or greater comprising applying to a selected application situs a matrix patch comprising

(a) a biocompatible polymer layer, wherein said biocompatible polymer is an adhesive selected from the group consisting of acrylics, vinyl acetates, natural and synthetic rubbers, ethylenevinylacetate copolymers, polysiloxanes, polyacrylates, polyurethanes, plasticized polyether block amide copolymers, plasticized styrene-rubber block copolymers, and mixtures thereof;

(b) an effective amount of a percutaneously absorbable basic drug having a pK.sub.a of about 8.0 or greater selected from the group consisting of oxybutynin, scopolamine, fluoxetine, epinephrine, morphine, hydromorphone, atropine, cocaine, buprenorphine, chlorpromazine, imipramine, desipramine, methylphenidate, methamphetamine, lidocaine, procaine, pindol, nadolol, carisoprodol, and acid addition salts thereof; and

(c) an effective amount of a permeation enhancer consisting essentially of triacetin.

2. The method of claim 1 wherein said effective amount of permeation enhancer comprises about 0.1% to about 50% by weight of triacetin.

3. The method of claim 2 wherein said basic drug is a member selected from the group consisting of oxybutynin and acid addition salts thereof.

4. The method of claim 3 wherein said effective amount of permeation enhancer comprises about 1% to about 40% by weight of triacetin.

5. The method of claim 4 wherein matrix patch further comprises a member selected from the group consisting of diluents, excipients, emollients, plasticizers, skin irritation reducing agents, carriers, and mixtures thereof.

6. The method of claim 5 wherein said basic drug is oxybutynin.

7. The method of claim 6 wherein said adhesive is an acrylic copolymer.

8. The method of claim 7 wherein the permeation enhancer comprises about 2% to about 20% by weight of triacetin.

9. The method of claim 8 wherein said matrix patch comprises a skin irritation reducing agent, wherein said skin irritation reducing agent is glycerin.

10. The method of claim 2 wherein said polymer layer is laminated to an adhesive.

11. The method of claim 2 wherein said polymer layer is overlaid with an adhesive.

12. A matrix patch for transdermal administration of a basic drug having a pK.sub.a of about 8.0 or greater comprising

(a) a biocompatible polymer layer, wherein said biocompatible polymer is an adhesive selected from the group consisting of acrylics, vinyl acetates, natural and synthetic rubbers, ethylenevinylacetate copolymers, polysiloxanes, polyacrylates, polyurethanes, plasticized polyether block amide copolymers, plasticized styrene-rubber block copolymers, and mixtures thereof;

(b) an effective amount of a percutaneously absorbable basic drug having a pK.sub.a of about 8.0 or greater selected from the group consisting of oxybutynin, scopolamine, fluoxetine, epinephrine, morphine, hydromorphone, atropine, cocaine, buprenorphine, chlorpromazine, imipramine, desipramine, methylphenidate, methamphetamine, lidocaine, procaine, pindolol, nadolol, carisoprodol, and acid addition salts thereof; and

(c) an effective amount of a permeation enhancer consisting essentially of triacetin.

13. The matrix patch of claim 12 wherein said effective amount of permeation enhancer comprises about 0.1% to about 50% by weight of triacetin.

14. The matrix patch of claim 13 wherein said basic drug is a member selected from the group consisting of oxybutynin and acid addition salts thereof.

15. The matrix patch of claim 14 wherein said effective amount of permeation enhancer comprises about 1% to about 40% by weight of triacetin.

16. The matrix patch of claim 15 wherein matrix patch further comprises a member selected from the group consisting of diluents, excipients, emollients, plasticizers, skin irritation reducing agents, carriers, and mixtures thereof.

17. The matrix patch of claim 16 wherein said basic drug is oxybutynin.

18. The matrix patch of claim 12 wherein said adhesive is an acrylic copolymer.

19. The matrix patch of claim 18 wherein the permeation enhancer comprises about 2% to about 20% by weight of triacetin.

20. The matrix patch of claim 19 wherein said matrix patch comprises a skin irritation reducing agent, wherein said skin irritation reducing agent is glycerin.

21. The matrix patch of claim 13 wherein said polymer layer is laminated to an adhesive.

22. The matrix patch of claim 13 wherein said polymer layer is overlaid with an adhesive.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Dow
Mallinckrodt
Cantor Fitzgerald
Fuji
Citi
Moodys
US Department of Justice
Novartis
AstraZeneca
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot